Engineering calcium signaling of astrocytes for neural-molecular computing logic gates

A dual channel rhodamine appended smart probe for selective recognition of Cu2+ and Hg2+ via "turn on" optical readout

A new rhodamine-6G hydrazone RHMA has been synthesized using rhodamine-6G hydrazide and 5-Allyl-3-methoxysalicylaldehyde. RHMA has been fully characterized with different spectroscopic methods and single crystal XRD. RHMA can selectively recognize Cu²⁺ and Hg²⁺ in aqueous media amongst other common competitive metal ions. A significant change in absorbance was observed with Cu²⁺ and Hg²⁺ ions with emergence of a new peak at λ_max 524 nm and 531 nm respectively. Hg²⁺ ions lead to "turn-on" fluorescence enhancement at λ_max 555 nm. This event of absorbance and fluorescence marks the opening of spirolactum ring causing visual color change from colorless to magenta and light pink.RHMA-Cu²⁺ and RHMA- Hg²⁺complexes are found to be reversible in presence of EDTA^2-ions. RHMA has real application in form of test strip. Additionally, the probe exhibits turn-on readout-based sequential logic gate-based monitoring of Cu²⁺ and Hg²⁺ at ppm levels, which may be able to address real-world challenges through simple synthesis, quick recovery, response in water, "by-eye" detection, reversible response, great selectivity, and a variety of output for accurate investigation.

Molecular modeling and dynamics studies of the synthetic small molecule agonists with GPR17 and P2Y1 receptor

The human Guanine Protein coupled membrane Receptor 17 (hGPR17), an orphan receptor that activates uracil nucleotides and cysteinyl leukotrienes is considered as a crucial target for the neurodegenerative diseases. Yet, the detailed molecular interaction of potential synthetic ligands of GPR17 needs to be characterized. Here, we have studied a comparative analysis on the interaction specificity of GPR17-ligands with hGPR17 and human purinergic G protein-coupled receptor (hP2Y1) receptors. Previously, we have simulated the interaction stability of synthetic ligands such as T0510.3657, AC1MLNKK, and MDL29951 with hGPR17 and hP2Y1 receptor in the lipid environment. In the present work, we have comparatively studied the protein-ligand interaction of hGPR17-T0510.3657 and P2Y1-MRS2500. Sequence analysis and structural superimposition of hGPR17 and hP2Y1 receptor revealed the similarities in the structural arrangement with the local backbone root mean square deviation (RMSD) value of 1.16 Å and global backbone RMSD value of 5.30 Å. The comparative receptor-ligand interaction analysis between hGPR17 and hP2Y1 receptor exposed the distinct binding sites in terms of geometrical properties. Further, the molecular docking of T0510.3657 with the hP2Y1 receptor have shown non-specific interaction. The experimental validation also revealed that Gi-coupled activation of GPR17 by specific ligands leads to the adenylyl cyclase inhibition, while there is no inhibition upon hP2Y1 activation. Overall, the above findings suggest that T0510.3657-GPR17 binding specificity could be further explored for the treatment of numerous neuronal diseases. Communicated by Ramaswamy H. Sarma.

Epidemic-like Calcium Signaling in Mobile Molecular Communication Networks

Molecular Communication is an emerging technology enabling communications in nano-networks. Ca2+ signal is one promising option of MC due to the important role in biometabolisms and the available characteristics in communication engineering. So far, scientists analyze Ca2+ signaling via bioexperiments and simulations. Current researches lack a mathematical model for quantitative analysis of Ca2+ signal propagation on the network scale. In this work, we investigate the propagation patterns of Ca2+ signals in bio-cellular network. Firstly, we propose an improved Ca2+ dynamics model to describe Ca2+ signals considering movements of cells and attenuation of Ca2+ concentration. Then, we perform multi-modal analysis through the waveform characteristics, and classify cells according to their states. Moreover, a mathematical model is put forward to analyze the propagation of calcium signals based on typical epidemic model. The proposed model fully considers the similarity between: 1) epidemic disease propagates among mobile individuals; 2) Ca2+ signal propagates among mobile cells. The proposed model is amended to fit the case considering unique characters of Ca2+ signal. Finally, simulation results show that the proposed Ca2+ propagation model is coincident with Monte Carlo simulation results, indicating that the model is helpful for understanding how far and how fast Ca2+ signal can propagate.

Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions

Hundreds of millions of people worldwide are affected by viral infections each year, and yet, several of them neither have vaccines nor effective treatment during and post-infection. This challenge has been highlighted by the COVID-19 pandemic, showing how viruses can quickly spread and impact society as a whole. Novel interdisciplinary techniques must emerge to provide forward-looking strategies to combat viral infections, as well as possible future pandemics. In the past decade, an interdisciplinary area involving bioengineering, nanotechnology and information and communication technology (ICT) has been developed, known as Molecular Communications. This new emerging area uses elements of classical communication systems to molecular signalling and communication found inside and outside biological systems, characterizing the signalling processes between cells and viruses. In this paper, we provide an extensive and detailed discussion on how molecular communications can be integrated into the viral infectious diseases research, and how possible treatment and vaccines can be developed considering molecules as information carriers. We provide a literature review on molecular communications models for viral infection (intra-body and extra-body), a deep analysis on their effects on immune response, how experimental can be used by the molecular communications community, as well as open issues and future directions.

Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth

Simple Summary

Glioblastoma multiforme (GBM), or glioblastoma chemotherapy, has one of the poorest improvements across all types of cancers. Despite the different rationales explored in targeted therapy for taming the GBM aggressiveness, its phenotypic plasticity, drug toxicity, and adaptive resistance mechanisms pose many challenges in finding an effective cure. Our manuscript reports the expression and prognostic role of orphan receptor GPR17 in glioma, the molecular mechanism of action of the novel ligand of GPR17, and provides evidence how the T0 agonist promotes glioblastoma cell death through modulation of the MAPK/ERK, PI3K–Akt, STAT, and NF-κB pathways. The highlights are as follows: GPR17 expression is associated with greater survival for both low-grade glioma (LGG) and GBM; GA-T0, a potent GPR17 receptor agonist, causes significant GBM cell death and apoptosis; GPR17 signaling promotes cell cycle arrest at the G1 phase in GBM cells; key genes are modulated in the signaling pathways that inhibit GBM cell proliferation; and GA-T0 crosses the blood–brain barrier and reduces tumor volume.

Abstract

Glioblastoma, an invasive high-grade brain cancer, exhibits numerous treatment challenges. Amongst the current therapies, targeting functional receptors and active signaling pathways were found to be a potential approach for treating GBM. We exploited the role of endogenous expression of GPR17, a G protein-coupled receptor (GPCR), with agonist GA-T0 in the survival and treatment of GBM. RNA sequencing was performed to understand the association of GPR17 expression with LGG and GBM. RT-PCR and immunoblotting were performed to confirm the endogenous expression of GPR17 mRNA and its encoded protein. Biological functions of GPR17 in the GBM cells was assessed by in vitro analysis. HPLC and histopathology in wild mice and an acute-toxicity analysis in a patient-derived xenograft model were performed to understand the clinical implication of GA-T0 targeting GPR17. We observed the upregulation of GPR17 in association with improved survival of LGG and GBM, confirming it as a predictive biomarker. GA-T0-stimulated GPR17 leads to the inhibition of cyclic AMP and calcium flux. GPR17 signaling activation enhances cytotoxicity against GBM cells and, in patient tissue-derived mesenchymal subtype GBM cells, induces apoptosis and prevents proliferation by stoppage of the cell cycle at the G1 phase. Modulation of the key genes involved in DNA damage, cell cycle arrest, and in several signaling pathways, including MAPK/ERK, PI3K–Akt, STAT, and NF-κB, prevents tumor regression. In vivo activation of GPR17 by GA-T0 reduces the tumor volume, uncovering the potential of GA-T0–GPR17 as a targeted therapy for GBM treatment. Conclusion: Our analysis suggests that GA-T0 targeting the GPR17 receptor presents a novel therapy for treating glioblastoma.